Condition
Colon Cancer Metastatic
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Terminated1
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07494578Active Not RecruitingPrimary
Observational Study Regarding the Combination of Fluoropyrimidine and Bevacizumab in Patients With mCRC
NCT07407465Phase 2Recruiting
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT03265080Phase 1TerminatedPrimary
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
Showing all 3 trials